Clark, J., Flaherty, L., Ernstoff, M., Koon, H., Milhem, M., Militello, G., . . . Lawson, D. (2014). A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01). J Immunother Cancer.
Styl cytowania ChicagoClark, Joseph, et al. "A Multi-center Study of High Dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) Therapy in Patients With BRAF(V600 )mutation Positive Metastatic Melanoma (proclivity 01)." J Immunother Cancer 2014.
Styl cytowania MLAClark, Joseph, et al. "A Multi-center Study of High Dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) Therapy in Patients With BRAF(V600 )mutation Positive Metastatic Melanoma (proclivity 01)." J Immunother Cancer 2014.